Clinical guidelines recommend febuxostat for chronic hyperuricaemia or gout when allopurinol is not tolerated or contraindicated. Data from the past 3 years suggest a steady increase in use of febuxostat in the UK, with usage approximately 19,000 patient-years in 2018.